Press Releases April 7, 2026 07:30 AM

Bread Financial Schedules First Quarter 2026 Earnings Conference Call for Apr. 23

Bread Financial Announces Date for Q1 2026 Earnings Call

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BFH

Bread Financial Holdings, a US-based tech-forward financial services company, has scheduled its first quarter 2026 earnings conference call for April 23, 2026. The company offers personalized payment, lending, and saving solutions, serving millions of consumers with co-brand, private label credit cards, and other financial products.

Bread Financial Schedules First Quarter 2026 Earnings Conference Call for Apr. 23
BFH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings call scheduled for April 23, 2026, at 8:30 a.m. ET to discuss Q1 2026 results.
  • Bread Financial operates in payment solutions including co-brand and private label credit cards across various sectors like travel, health, technology, and apparel.
  • The company provides general purpose credit cards and saving products emphasizing personalized financial services for consumers.

COLUMBUS, Ohio, April 07, 2026 (GLOBE NEWSWIRE) -- Bread Financial® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions will host a conference call on Thursday, Apr. 23, 2026, at 8:30 a.m. ET to discuss the company’s first quarter 2026 results.

Conference Call/Webcast Information
Participants can register in advance here, and the conference call will be available at the company’s investor relations website. Analysts planning to participate in the Q&A can register in advance here. Additionally, there will be several slides accompanying the webcast. Please go to the website at least 15 minutes prior to the call to register, as well as download and install any necessary software. The webcast will also be archived on the investor relations website.

About Bread Financial®
Bread Financial® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, health & beauty, technology, electronics, jewelry, home and specialty apparel through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

Contacts
Brian Vereb — Investor Relations
[email protected]

Susan Haugen – Investor Relations
[email protected]

Rachel Stultz — Media
[email protected]  


Risks

  • Financial performance may be impacted by macroeconomic conditions affecting consumer spending in sectors such as travel, entertainment, and retail.
  • Earnings outcomes may be influenced by credit risk and customer repayment behaviors inherent to lending and credit card businesses.
  • Market competition from other financial services and fintech companies could affect Bread Financial's growth and profitability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026